Download MendeleyStructure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones.
Faig, M., Bianchet, M.A., Winski, S., Hargreaves, R., Moody, C.J., Hudnott, A.R., Ross, D., Amzel, L.M.(2001) Structure 9: 659-667
- PubMed: 11587640
- DOI: https://doi.org/10.1016/s0969-2126(01)00636-0
- Primary Citation of Related Structures:
1GG5, 1H66, 1H69 - PubMed Abstract:
NAD(P)H:quinone acceptor oxidoreductase (QR1) protects animal cells from the deleterious and carcinogenic effects of quinones and other electrophiles. Remarkably, the same enzyme activates cancer prodrugs that become cytotoxic only after two-electron reduction. QR1's ability to bioactivate quinones and its elevated expression in many human solid tumors makes this protein an excellent target for enzyme-directed drug development. Until now, structural analysis of the mode of binding of chemotherapeutic compounds to QR1 was based on model building using the structures of complexes with simple substrates; no structure of complexes of QR1 with chemotherapeutic prodrugs had been reported.
Organizational Affiliation:
Department of Biophysics and Biophysical Chemistry, Johns Hopkins Medical School, Baltimore, MD 21205, USA.
